Nexalis Therapeutics (ASX:NX1)
ASX announcement history & article coverage
Transparent by design.
Announcments by Nexalis Therapeutics (ASX:NX1) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Removal of draft wording in the directors report HY accounts
Nexalis Therapeutics reports increased loss, funding facility cancellation, and clinical trial suspension
Half Yearly Report and Accounts
Nexalis Therapeutics reports increased half-year loss and funding facility cancellation, suspends clinical trials
Jun26 Appendix 4C Cash Flow Report
Nexalis Therapeutics reports positive operating cash flow and full repayment of RDTI funding facility; Linlithgow debt facility cancelled
Jun26 Quarterly Activities Report
Nexalis completes IRX-616a Phase 1 dosing; funding facility cancelled, clinical programs under review
Change in substantial holding
Change of Director's Interest Notice - Sean Williams
Change of Director's Interest Notice - Darryl Davies
Notification of cessation of securities - NX1
Notification regarding unquoted securities - NX1
Issue of director share rights post shareholder approval
Nexalis Therapeutics issues share rights to directors in lieu of fees with vesting tied to Phase 2 trial success
Update on Funding Facility and Clinical Program
Nexalis Therapeutics halts Point8 funding talks, completes IRX-616a Phase 1 trial with positive results, reassesses clinical plans
Director Appointment/Resignation